• Publications
  • Influence
Genome‐Wide Association Study Confirms SNPs in SNCA and the MAPT Region as Common Risk Factors for Parkinson Disease
TLDR
Three independent genome‐wide association studies (GWAS) have investigated the genetic susceptibility to PD and implicated several genes as PD risk loci with strong, but not genome-wide significant, associations.
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.
TLDR
Improvements associated with BoNT/B treatment were greatest for patients who received the 10,000-U dose, and Botulinum toxin type B (NeuroBloc) is safe and efficacious at 5,000 U and 10, thousand U for the management of patients with cervical dystonia.
Visuospatial impairment in Parkinson's disease
TLDR
The presence of visuospatial deficits in PD patients, with a changing pattern of impairment related to dementia and progression of the disease, is supported.
Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia
TLDR
BotB is safe, well tolerated, and efficacious in the treatment of cervical dystonia at the doses tested and a statistically significant treatment effect and a dose response.
SRRM2, a Potential Blood Biomarker Revealing High Alternative Splicing in Parkinson's Disease
TLDR
The consistent dysregulation of the RNA splicing factor SRRM2 in two different PD neuronal sources and in PD blood but not in blood of other neurologically diseased patients makes SR RM2 a strong candidate gene for PD and draws attention to the role of RNAsplicing in the disease.
Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: Results of the first US randomized, double‐blind, placebo‐controlled study
TLDR
The results confirm previous reports that Dysport (500 units) is safe, effective, and well‐tolerated in patients with cervical dystonia.
Adult‐onset subacute sclerosing panencephalitis: Case reports and review of the literature
TLDR
Although the course of the disease was progressive and fatal in the majority, there appeared to be a higher rate of spontaneous remission as compared with childhood‐onset SSPE.
Treatment of Painful Limbs/Moving Extremities with Botulinum Toxin Type A Injections
TLDR
2 patients with PLMT in whom analgesic multipharmacy failed to relieve their severe lower limb pain are described in whom Botulinum toxin type A (Botox, Allergan, Inc.) resulted in both pain relief and improvement of involuntary movements.
...
1
2
3
4
5
...